Companies
IPO: ORTX
IPO: FRLN
IPO: ACHL
IPO: MGTX
Acquired by Facebook
IPO: BKNG
IPO: GENinCode
IPO: DSS/ Bioclinica
Explore our investments
-
Life Sciences investments
-
Investing since2016In collaboration with UCL Business
-
Total investment> $2bnOver $2bn of follow on funding for our companies
-
Public offerings4 IPOsFour Nasdaq IPOs since 2018
Featured investments
Bloomsbury GTX launches with Seed financing of £5m to develop the promise of gene therapy
Bloomsbury GTX raises £5m Seed funding to develop curative gene therapy treatments
Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet?
Companies
-
Achilles TherapeuticsBiopharmaceutical company developing precision T cell therapies
Life SciencesNasdaq IPO -
Apollo Therapeuticsbiopharmaceutical company advancing a robust pipeline of potentially transformative therapeutic programs Life SciencesGrowth
-
Bloomsbury AIEnabling everyone to easily create their own question-answering system Life SciencesExited
-
Bloomsbury GTXBiotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases Life SciencesEarly Stage
-
EpsilogenImmuno-oncology company targeting cancer with the IgE class of antibodies Life SciencesEarly Stage
-
Freeline TherapeuticsBiopharmaceutical company focused on the development of liver-directed gene therapies Life SciencesNasdaq IPO
-
Meira GTXVertically integrated, clinical stage gene therapy company Life SciencesNasdaq IPO
-
NovalGenImmuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer Life SciencesEarly Stage
-
Orchard TherapeuticsBiotechnology company bringing transformative gene therapies to patients with serious and life-threatening orphan diseases Life SciencesNasdaq IPO
-
Panangium TherapeuticsBiologic for retinal disease targeting a novel alternative pathway to VEGF Life SciencesEarly Stage
-
Quell TherapeuticsCell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions Life SciencesGrowth
